Library › FNA technique, image-guided sampling and rapid on-site evaluation
FNA technique, image-guided sampling and rapid on-site evaluation
Last reviewed 2026-11-10 by a board-certified pathologist. 80 references.
Palpation-Guided Fine-Needle Aspiration and Its Complications
Definition. Fine-needle aspiration (FNA) is a biopsy method in which a thin needle obtains cells and small tissue fragments from a mass for cytologic diagnosis. A palpable lesion can be targeted by palpation alone. Deeper or smaller lesions require imaging guidance. The Papanicolaou Society of Cytopathology (PSC) states that FNA can replace many surgical biopsies. Its reliability is greatest with rapid assessment of the aspirate and a team approach among cytopathologist, radiologist and clinician. Training and maintained competency are central to its success (PSC 1997). The British Society for Clinical Cytology (BSCC) Code of Practice adds that FNA may be taken by cytopathologists, radiologists, nurses or clinicians, who must be trained, experienced and subject to regular audit (Kocjan et al. 2009).
Related page: Normal pancreas, gastrointestinal contaminants and EUS-guided sampling (EUS-FNA technique for the pancreas) Related page: Lung FNA Adequacy and Rapid On-Site Evaluation (adequacy criteria for lung and mediastinal FNA) Related page: Thyroid Nodule Selection for FNA and Aspiration Technique (thyroid nodule selection, needle gauge and capillary sampling)
Practice guidelines and consensus documents for fine-needle aspiration
| Document | Year | Scope | Provisions relevant to technique and safety |
|---|---|---|---|
| PSC guidelines for FNA procedure and reporting | 1997 | All FNA | Rapid assessment and a team approach maximize reliability; aspirators who persistently produce unsatisfactory aspirates at a rate above 15% are identified and given remedial training; quality assurance and quality improvement programs monitor competency (PSC 1997) |
| NCI Thyroid FNA State of the Science Conference | 2008 | Thyroid | Needles, devices and methods; local anesthesia; lesion location and size; ultrasound for palpable nodules; operator specialty; number of passes; preparation methods; adequacy; adverse reactions (Pitman et al. 2008; Baloch et al. 2008) |
| BSCC Code of Practice for FNA cytology | 2009 | All FNA | Setting up FNA services, patient management, sampling, slide preparation, ancillary-test collection, rapid on-site assessment, classification and reporting (Kocjan et al. 2009) |
| PSC guidelines for pancreatobiliary sampling | 2014 | Pancreas and bile duct | EUS-FNA technique, suction and passes (Brugge et al. 2014) |
| ESGE technical guideline for EUS-guided sampling | 2017 | GI tract, pancreas, lymph nodes | Needle size, suction, release of negative pressure, fanning, passes, histologic preparations (Polkowski et al. 2017) |
| CAR/CAIR guideline on periprocedural bleeding risk | 2026 | Image-guided and superficial procedures | Low-risk and high-risk procedure categories; INR and platelet thresholds based on the SIR 2019 guideline (Harper et al. 2026) |
Operator training and the accuracy of palpation-guided FNA
The accuracy of FNA depends on the training of the operator (Ljung et al. 2001).
| Measure (1,043 breast FNAs, 1992) | Formally trained operators | Operators without formal training |
|---|---|---|
| Number of FNAs | 729 | 314 |
| Training definition | At least 150 supervised FNAs in fellowship or equivalent, and at least 100 FNAs in the study year | Median of 2 FNAs in the study year (range 1–43) |
| Cancers missed | 2% | 25% |
| Patients with benign lesions sent to surgery | 8% | 30% |
| Specimen quality | More cellular; less often nondiagnostic | Less cellular; more often nondiagnostic |
Source: Ljung et al. 2001. Follow-up was at least 2 years, by linkage to the Northern California Cancer Registry.
- Head and neck FNA. In an earlier study cited by Wu, the sensitivity of head and neck FNA was 96% when a cytopathologist performed the procedure and 67% when a noncytopathologist performed it (Wu 2011).
- Inadequate samples. The BSCC states that inadequate samples seriously compromise the accuracy and cost-effectiveness of FNA (Kocjan et al. 2009).
- Experience for thyroid FNA. The NCI conference states that the physician who performs thyroid FNA in an institutional or office practice should be experienced (Baloch et al. 2008).
Needle and sampling technique in palpation-guided FNA
Aspiration and capillary (non-aspiration) sampling
- Aspiration technique. A syringe applies negative pressure while the needle moves through the lesion (Zajdela et al. 1987; Brugge et al. 2014).
- Capillary (non-aspiration) technique. The needle alone, without a syringe or suction, is moved through the lesion, and cells enter the lumen by capillary action. Zajdela and colleagues compared this method with classical aspiration in breast tumors. The insufficient rate was 5.5% in 635 tumors sampled without aspiration in 1981 and 6% in 7,877 tumors sampled with aspiration from 1954 to 1980. Trauma was reduced, and the operator perceived the tumor and its consistency directly (Zajdela et al. 1987).
- Capillary sampling of thyroid nodules. Capillary sampling and needle gauge for thyroid nodules are covered in Thyroid Nodule Selection for FNA and Aspiration Technique (Moss et al. 2018).
NCI conference technique for thyroid FNA
The summation of the 2007 National Cancer Institute (NCI) Thyroid FNA State of the Science Conference gives the following technique (Baloch et al. 2008).
| Variable | NCI conference statement |
|---|---|
| Needle gauge | 25–27 gauge preferred for initial biopsies, with needle size increased if needed |
| Larger needles | Reserved for drainage of viscous colloid cyst contents |
| Suction | Native suction from surface tension in smaller needles |
| Dwell time and movement | 2–5 seconds in the nodule, with 3 forward and back oscillations per second |
| Slides | 1–2 slides per biopsy pass |
| Passes | 2–5 passes is a reasonable number to try to ensure an adequate sample |
| Protocol with rapid interpretation | 2 biopsies from different areas of the lesion, with a representative slide stained for adequacy |
| Protocol without rapid interpretation | 2–5 biopsies from different sites |
| Local anesthesia | 1% lidocaine or 2% lidocaine with epinephrine 1:100,000; local anesthetic may cause difficulty in sample evaluation |
| Complex nodules | The wall, solid elements and suspicious calcified areas are sampled, avoiding cystic areas |
Source: Baloch et al. 2008.
Suction, blood dilution and number of passes
- Blood. Excessive suction increases the amount of blood in the sample. Highly vascular lesions are aspirated with minimal suction (Brugge et al. 2014).
- Number of passes. In a randomized study of 240 solid or predominantly solid thyroid nodules sampled under ultrasound guidance, adequacy was 91.3% with one pass, 92.5% with two passes and 92.5% with three passes. The differences were not significant (Chen et al. 2023).
Smear preparation and fixation of FNA material
| Preparation | Fixation | Processing |
|---|---|---|
| Air-dried direct smear | Air-drying | Romanowsky-type stain such as Diff-Quik |
| Wet-fixed direct smear | 95% ethanol | Papanicolaou stain |
| Cell block or tissue fragments | Formalin | Paraffin embedding and histologic sections |
Sources: Satturwar et al. 2020; Polkowski et al. 2017.
- Toluidine blue. Toluidine blue may also be used and requires only one drop of stain (Satturwar et al. 2020).
The pathologist-performed FNA clinic
In a pathologist-performed FNA clinic, the cytopathologist performs the aspiration (Conrad et al. 2018).
Ultrasound guidance in the pathologist-performed clinic
Cytopathologists who perform FNA have added ultrasound guidance to palpation (Conrad et al. 2018).
- UCLA departmental FNA clinic. Among 1,029 cytopathologist-performed FNAs, 449 (43.6%) were ultrasound-guided and 580 (56.4%) were palpation-guided. The nondiagnostic rate was 6.7% with ultrasound guidance and 20.7% with palpation. Of the 495 cases with follow-up, the discordance rate was 5.4% with ultrasound guidance and 12.8% with palpation (Conrad et al. 2018).
- Single cytopathologist, head and neck. In 200 consecutive head and neck FNAs by one cytopathologist, the nondiagnostic rate was 7% with palpation and 1% with ultrasound guidance. Specificity rose from 50% to 86%, and negative predictive value from 33% to 100%. Sensitivity was 96% with palpation and 100% with ultrasound (Wu 2011).
| Site (Conrad et al. 2018) | Nondiagnostic, ultrasound-guided | Nondiagnostic, palpation-guided |
|---|---|---|
| Thyroid | 6.0% | 33.3% |
| Head and neck | 6.6% | 21.2% |
| Salivary gland | 6.2% | 17.1% |
| All sites | 6.7% | 20.7% |
Workflow, consent and documentation in the pathologist-performed FNA clinic
- Practice survey. In an American Society of Cytopathology survey (December 2022 to March 2023), 174 respondents completed the qualifying question, 68% of them from the USA. Nearly one-half (67 of 137) reported that pathologists in their practice performed ultrasound-guided FNA. Over one-half (70 of 123) worked in settings with 0 to 50 ultrasound-guided FNAs per year, and 19% in settings with more than 300 (Kurtycz et al. 2025).
- Standard procedural steps. Most respondents, though not all, reported informed consent, site verification, a procedure time-out, and documentation of the procedure and of the ultrasound findings (Kurtycz et al. 2025).
- Barriers. Training, equipment, reimbursement and procedural variability were significant barriers to adoption of pathologist-performed ultrasound-guided FNA (Kurtycz et al. 2025).
- Consent law. The NCI thyroid conference states that legislation on the conditions for consent varies greatly by state. Consent policies and forms are therefore based on state regulations (Baloch et al. 2008).
- Content of consent. Written consent documents, if used, describe the procedure and its potential risks and complications. Hematoma, the most frequent complication, is mentioned. The possibility of a noncontributory (nondiagnostic) result may also be mentioned. False-negative and false-positive rates are optional (Baloch et al. 2008).
- Requisition data for thyroid FNA. The minimum data are the location and estimated size of the nodule; history of hypothyroidism, autoimmune thyroiditis, antithyroid antibodies or Graves disease; history of radioiodine or external radiation with dates; personal history of cancer; and family history of thyroid cancer. Prior FNA, levothyroxine therapy, the thyroid-stimulating hormone level and imaging results are optional (Baloch et al. 2008).
| Element | Content | Source |
|---|---|---|
| Consent | According to state law; describes the procedure, risks and complications; mentions hematoma and possible nondiagnostic result | Baloch et al. 2008 |
| Site verification and time-out | Reported by most surveyed practices performing ultrasound-guided FNA | Kurtycz et al. 2025 |
| Procedure documentation | Documentation of the procedure and of ultrasound findings reported by most surveyed practices | Kurtycz et al. 2025 |
| Requisition (thyroid) | Nodule location and size; thyroid disease, cancer, radiation and family history | Baloch et al. 2008 |
CPT codes for the FNA procedure
In June 2017 the CPT Editorial Panel deleted CPT 10022, revised CPT 10021 and created nine new codes for FNA with and without imaging guidance. Imaging guidance is included in the code descriptors. The codes took effect for calendar year 2019 (CMS CY 2019 Physician Fee Schedule final rule, 2018).
| Guidance | First lesion | Each additional lesion |
|---|---|---|
| None | 10021 | 10004 |
| Ultrasound | 10005 | 10006 |
| Fluoroscopy | 10007 | 10008 |
| CT | 10009 | 10010 |
| MR | 10011 | 10012 |
Source: CMS CY 2019 Physician Fee Schedule final rule, 2018.
- Unit of service. The unit of service for the FNA biopsy codes (CPT 10004–10012 and 10021) is the separately identifiable lesion. Multiple passes into the same lesion are reported as one unit. A separate unit may be reported for a distinct, separately identifiable lesion (CMS NCCI Policy Manual, Chapter III, 2026).
- FNA with another biopsy of the same lesion. FNA codes are not reported with a biopsy code for the same lesion. When an inadequate FNA is followed at the same encounter by another type of biopsy of that lesion, only one code is reported, either the biopsy code or the FNA code (CMS NCCI Policy Manual, Chapter III, 2026).
Complications of fine-needle aspiration
Thyroid FNA is a safe procedure with rare complications, which are mainly minor (Park et al. 2023).
| Complication | Setting | Frequency or finding | Source |
|---|---|---|---|
| Hematoma or hemorrhage | Thyroid FNA | 0% to 6.4% of patients in 15 studies | Park et al. 2023 |
| Vasovagal reaction, vocal cord palsy, tracheal puncture | Thyroid FNA | Rarely described | Park et al. 2023 |
| Hematoma in patients on antithrombotic or anticoagulant drugs | Ultrasound-guided thyroid FNA | 0.89% on these drugs and 0.49% without them (P = 0.41); all managed conservatively | Khadra et al. 2018 |
| Pneumothorax | Palpation-guided breast FNA in a woman with Poland syndrome | Single case, treated conservatively; attributed to absent pectoral muscles, with image guidance advised in such patients | Salhab et al. 2005 |
| Infarction of the target lesion | Parotid Warthin tumor | Painful swelling 15 days after FNA; loss of enhancement and of Doppler flow | Puttamreddy et al. 2026 |
| Serious adverse events | EBUS-TBNA and EUS-FNA of mediastinal and hilar nodes and central lung lesions, 16,181 patients | 0.14% overall; 0.30% with EUS and 0.05% with EBUS; no deaths | von Bartheld et al. 2014 |
| Death | Ultrasound-guided abdominal FNA, 10,766 biopsies | 0.018%; two deaths from hemoperitoneum in hepatocellular carcinoma | Fornari et al. 1989 |
| Major complications | Ultrasound-guided abdominal FNA, 10,766 biopsies | 0.18% | Fornari et al. 1989 |
Complications of CT-guided lung FNA and of navigational bronchoscopy are given in Image-guided fine-needle aspiration and needle biopsy.
Complications of abdominal fine-needle biopsy
- Deaths by organ. A literature review and two questionnaire surveys identified 33 deaths after percutaneous abdominal fine-needle biopsy. Of these, 21 followed biopsy of liver lesions, and 17 of the 21 were caused by hemorrhage. Six followed pancreatic biopsy, and five of the six were caused by pancreatitis (Smith 1991).
- Mortality rates. The questionnaires recorded mortality rates of 0.006% and 0.031% in US hospitals. Two European questionnaires recorded 0.008% and 0.018% (Smith 1991).
Needle tract seeding by site
Needle tract seeding is implantation of tumor cells along the path of the needle. Its reported frequency varies with the organ and the tumor type.
| Site and procedure | Frequency or finding | Tumors most often reported | Source |
|---|---|---|---|
| Thyroid FNA | 0.02% to 0.19% in three studies | Thyroid carcinoma | Park et al. 2023 |
| Percutaneous abdominal fine-needle biopsy | 0.003% to 0.009% in four questionnaire surveys | Pancreatic carcinoma: 10 of 23 reported cases | Smith 1991 |
| Ultrasound-guided abdominal FNA, Italian multicenter series of 10,766 biopsies | Pancreatic carcinoma in 5 of 8 reported seeding cases | Pancreatic carcinoma | Fornari et al. 1989 |
| EUS-FNA | Frequency not established; case reports increasing, especially in Japan | Lesions in and adjacent to the gastrointestinal tract | Minaga et al. 2017 |
| Percutaneous core biopsy of retroperitoneal sarcoma | 0.37% in pooled data from 4 referral centers | Retroperitoneal sarcoma | Berger-Richardson and Swallow 2017 |
| Core biopsy of extremity sarcoma | Only a few cases reported | Extremity sarcoma | Berger-Richardson and Swallow 2017 |
| Percutaneous transthoracic needle biopsy, stage I non-small cell carcinoma | Pleural recurrence in 6.3% after biopsy and 2.8% without it; not significant after propensity matching | Non-small cell carcinoma | Ahn et al. 2019 |
- Lung. In 830 resected stage I non-small cell carcinomas, visceral pleural invasion was the only factor associated with pleural recurrence after matching. A transfissural approach did not increase the risk (Ahn et al. 2019). A meta-analysis of 8 cohort studies (2,760 patients) found no overall increase in pleural recurrence after transthoracic biopsy. Biopsy increased the risk of pleural recurrence for subpleural lesions (Li et al. 2020).
- Sarcoma. En bloc excision of the needle tract with the tumor is often performed but is not associated with better oncologic outcomes. For gastrointestinal stromal tumor, peritoneal dissemination after percutaneous biopsy is a theoretical and unproven risk, and EUS is the preferred route of biopsy (Berger-Richardson and Swallow 2017).
- Hepatocellular carcinoma. Seeding after biopsy of hepatocellular carcinoma is covered in Normal Liver, FNA Indications and Reactive Changes on Liver FNA.
Complications of endosonographic sampling of the mediastinum
- Infection. In a systematic review of 190 studies, infectious serious adverse events were the most frequent (0.07%). They occurred mainly in patients with cystic lesions and sarcoidosis (von Bartheld et al. 2014).
- Lung cancer. Complications were rare in patients with lung cancer (von Bartheld et al. 2014).
- Underreporting. Follow-up information was missing in half of the studies, so the true incidence may be higher (von Bartheld et al. 2014).
Bleeding risk and antithrombotic drugs at the time of FNA
- Procedural risk category. The 2026 CAR/CAIR guideline classifies superficial biopsy as low risk. This covers biopsy of palpable lesions, easily compressible lymph nodes of the neck, axilla and groin, breast, soft tissue, thyroid and superficial bone. Biopsy of solid deep organs (liver, kidney, prostate), lung biopsy and biopsy of deep lymph nodes or soft tissue (retroperitoneal, pelvic, mediastinal) are high risk (Harper et al. 2026).
- Needle size. Most superficial biopsies use needles of 25G to 18G (Harper et al. 2026).
| Laboratory testing (normal liver function) | Low-risk procedure | High-risk procedure |
|---|---|---|
| Screening | Platelet count and INR not screened routinely | Platelet count and INR screened routinely |
| INR, if already measured | Corrected to within 2.0–3.0 | Corrected to below 1.8 |
| Platelets | Transfused below 20 × 10⁹/L | Transfused below 50 × 10⁹/L |
Source: Harper et al. 2026. The thresholds are based on, and unchanged from, the Society of Interventional Radiology (SIR) 2019 guideline.
- Thyroid series. In 803 patients (1,568 lesions) who underwent ultrasound-guided thyroid FNA by one surgeon, 148 patients (336 lesions) were taking one or more antithrombotic or anticoagulant drugs. The drugs included aspirin, clopidogrel, warfarin, rivaroxaban and ticagrelor. Hematoma rates did not differ significantly, and no complication required intervention (Khadra et al. 2018).
- Direct oral anticoagulants. A review concluded that continuing dabigatran, rivaroxaban or apixaban before ultrasound-guided thyroid FNA is reasonable. The conclusion rested on the safety of minor procedures in patients on these drugs and on the safety of FNA in patients on older anticoagulants (Lyle and Dean 2015).
Histologic alterations after fine-needle aspiration
Worrisome histologic alterations following FNA of the thyroid (WHAFFT) are changes in the resected gland caused by the needle. They can mimic malignancy.
- Frequency. Of 265 thyroid excisions that followed FNA, 38.49% showed WHAFFT. No WHAFFT lesions were present in 30 control glands (Pandit and Phulpagar 2001).
- Acute and chronic lesions. Acute lesions were present in 30 cases and chronic lesions in 72. Hemorrhage and fibrosis were the most common (Pandit and Phulpagar 2001).
- Worrisome lesions. Nuclear atypia, vascular changes, capsular pseudoinvasion and metaplasia were present in 32 cases (12.07%) (Pandit and Phulpagar 2001).
Infarction of Warthin tumor after fine-needle aspiration
Infarction of a Warthin tumor after FNA is rare and can mimic malignancy on imaging and histology. In a reported case, a 3-cm parotid Warthin tumor with internal vascularity became painful 15 days after FNA. CT then showed complete loss of internal enhancement, and Doppler ultrasound showed absent internal flow. Excision about 4 weeks after FNA showed an infarcted Warthin tumor without malignancy (Puttamreddy et al. 2026).
| Post-FNA alteration | Malignant mimic | Distinguishing information |
|---|---|---|
| Capsular pseudoinvasion along the needle track | Capsular invasion in follicular carcinoma | Recent FNA; hemorrhage and fibrosis along a linear track (Pandit and Phulpagar 2001) |
| Vascular changes | Vascular invasion | Recent FNA; associated acute or chronic reparative changes (Pandit and Phulpagar 2001) |
| Nuclear atypia near the track | Papillary carcinoma nuclear features | Location adjacent to hemorrhage and fibrosis (Pandit and Phulpagar 2001) |
| Infarction of a Warthin tumor | Necrotic carcinoma | Pre-FNA diagnosis of Warthin tumor; new loss of enhancement and Doppler flow (Puttamreddy et al. 2026) |
Sources of error in palpation-guided FNA and post-FNA interpretation
| Error | Consequence | Correct practice |
|---|---|---|
| Aspiration of a vascular thyroid nodule with strong suction | Blood-diluted, nondiagnostic smears | Capillary sampling with a 24- to 27-gauge needle; minimal suction in vascular lesions (Moss et al. 2018; Brugge et al. 2014) |
| Untrained or infrequent operator | Missed cancers and unnecessary surgery | Formal training and audit (Ljung et al. 2001; Kocjan et al. 2009) |
| Persistent unsatisfactory rate above 15% | Repeat procedures and diagnostic delay | Remedial training (PSC 1997) |
| Routine INR and platelet testing before superficial FNA | Unnecessary testing and delay | No routine screening for low-risk procedures (Harper et al. 2026) |
| Capsular pseudoinvasion interpreted as invasion | Overdiagnosis of follicular carcinoma | Correlation with the FNA history and the track morphology (Pandit and Phulpagar 2001) |
| Post-FNA infarction interpreted as necrotic carcinoma | Unnecessary aggressive treatment | Correlation with the pre-FNA cytology and imaging (Puttamreddy et al. 2026) |
FNA complication lookup
Image-Guided Fine-Needle Aspiration and Needle Biopsy
Definition. Image-guided sampling is fine-needle aspiration (FNA) or needle biopsy in which ultrasound, computed tomography (CT), endoscopic ultrasound (EUS), endobronchial ultrasound (EBUS) or a bronchoscopic navigation platform places the needle in the target. Ultrasound guidance allows sampling of smaller nonpalpable lesions (Wu 2011). It also lowers the nondiagnostic rate of superficial FNA compared with palpation (Danese et al. 1998; Conrad et al. 2018).
Related page: Normal pancreas, gastrointestinal contaminants and EUS-guided sampling (EUS-FNA and FNB of the pancreas, needle choice and gastrointestinal contaminants) Related page: Lung FNA Adequacy and Rapid On-Site Evaluation (adequacy criteria and EBUS-TBNA in mediastinal staging)
Image-guided sampling methods and their targets
| Method | Guidance | Targets | Source |
|---|---|---|---|
| Ultrasound-guided FNA | Transcutaneous ultrasound | Thyroid, head and neck, salivary gland and other superficial lesions | Conrad et al. 2018; Wu 2011 |
| CT-guided transthoracic needle aspiration (TTNA) or core biopsy | CT | Peripheral lung lesions | Rivera et al. 2013; Heerink et al. 2017 |
| EUS-guided FNA and fine-needle biopsy (FNB) | Echoendoscope in the upper gastrointestinal tract | Solid masses, lymph nodes, pancreatic cysts, subepithelial lesions | Polkowski et al. 2017; Deprez et al. 2022 |
| EBUS-guided transbronchial needle aspiration (EBUS-TBNA) | Convex-probe EBUS bronchoscope | Mediastinal and hilar structures and parabronchial lung masses | Wahidi et al. 2016 |
| Radial-probe EBUS | Radial ultrasound probe through the bronchoscope | Peripheral lung lesions | Steinfort et al. 2011 |
| Electromagnetic navigation bronchoscopy (ENB) | Electromagnetic guidance of tools to the lesion | Peripheral lung lesions | Gex et al. 2014; Folch et al. 2019 |
| Robotic-assisted bronchoscopy (RAB) | Robotic bronchoscope platform | Peripheral lung lesions | Zhang et al. 2024; Ost et al. 2026 |
Ultrasound-guided FNA of thyroid nodules
- Meta-analysis. In 11 studies (2,382 subjects), ultrasound-guided FNA had a sensitivity of 90% and a specificity of 80% for thyroid malignancy. Palpation-guided FNA had a sensitivity of 76% and a specificity of 77%. The area under the curve was 0.92 with ultrasound guidance and 0.827 with palpation (Tarigan et al. 2022).
| Measure (Danese et al. 1998; 4,986 palpation-guided and 4,697 sonography-guided FNAs over 15 years) | Palpation-guided FNA | Sonography-guided FNA |
|---|---|---|
| Valid cytologic diagnosis | 85.9% | 91.5% |
| Inadequate specimens | 8.7% | 3.5% |
| False-negative results among operated nodules | 2.3% | 1% |
| Sensitivity | 91.8% | 97.1% |
| Specificity | 68.8% | 70.9% |
| Overall diagnostic accuracy | 72.6% | 75.9% |
CT-guided transthoracic needle sampling of the lung
Diagnostic performance of transthoracic needle aspiration
- Sensitivity. The pooled sensitivity of TTNA for lung cancer was 90% in the American College of Chest Physicians (ACCP) 2013 guideline. Sensitivity trended lower for lesions smaller than 2 cm (Rivera et al. 2013).
- Comparison with bronchoscopy. TTNA carries a higher rate of pneumothorax than bronchoscopic procedures (Rivera et al. 2013).
- Small cell and non-small cell carcinoma. The accuracy of cytology in separating small cell from non-small cell carcinoma across diagnostic modalities was 98% (Rivera et al. 2013).
Complications of CT-guided lung FNA and core biopsy
A meta-analysis pooled 17 FNA studies (4,620 procedures) and 32 core biopsy studies (8,133 procedures) published from 2000 to 2015 (Heerink et al. 2017).
| Complication | FNA (95% CI) | Core biopsy (95% CI) |
|---|---|---|
| Any complication | 24.0% (18.2–30.8%) | 38.8% (34.3–43.5%) |
| Major complication | 4.4% (2.7–7.0%) | 5.7% (4.4–7.4%) |
| Pneumothorax | 18.8% (14.6–23.9%) | 25.3% (22.2–28.6%) |
| Pneumothorax requiring intervention | 4.3% (2.7–7.0%) | 5.6% (4.3–7.3%) |
| Pulmonary hemorrhage | 6.4% (2.5–15.2%) | 18.0% (13.4–23.8%) |
| Hemoptysis | 1.7% (0.9–3.1%) | 4.1% (2.8–6.1%) |
Source: Heerink et al. 2017. Hemothorax was reported in only five studies, too few for a pooled rate. Needle tract seeding, air embolism and death were not reported in the included studies.
- Definition of major complication. Major complications were pneumothorax requiring intervention, hemothorax, air embolism, needle tract seeding and death (Heerink et al. 2017).
- Risk factors for FNA. A larger needle diameter increased overall complications. More traversed lung parenchyma and a smaller lesion increased major complications (Heerink et al. 2017).
EUS-guided FNA and FNB of solid masses, lymph nodes and subepithelial lesions
ESGE technical recommendations for EUS-guided sampling
The 2017 ESGE technical guideline covers EUS-guided sampling of solid masses, lymph nodes and pancreatic cysts in the gastrointestinal tract (Polkowski et al. 2017).
| Topic | ESGE 2017 statement | Strength and evidence |
|---|---|---|
| Needle for routine sampling of solid masses and lymph nodes | 25G or 22G | Strong; high quality |
| Needle type | FNA and FNB needles equally recommended | Strong; high quality |
| Core tissue as the primary aim | 19G FNA or FNB needles, or 22G FNB needles | Weak; low quality |
| Suction with 25G or 22G FNA needles | 10-mL syringe suction | Strong; high quality |
| Residual negative pressure | Neutralized before the needle is withdrawn | Weak; moderate quality |
| Stylet | No recommendation for or against with FNA needles; suggested with FNB needles | Strong, high quality (FNA); weak, low quality (FNB) |
| Needle movement | Fanning throughout the lesion | Weak; moderate quality |
| Passes without on-site evaluation | 3–4 passes with an FNA needle or 2–3 with an FNB needle | Weak; low quality |
| Specimen evaluation | Histologic preparations (cell blocks or paraffin-embedded fragments) in addition to smears | Weak; low quality |
Source: Polkowski et al. 2017.
The 2025 ESGE Technical and Technology Review updated the needle and antibiotic statements for pancreatic lesions; the current recommendations are given in Normal pancreas, gastrointestinal contaminants and EUS-guided sampling (Facciorusso et al. 2025).
Subepithelial lesions of the gastrointestinal tract
- Characterization. EUS is the best tool to characterize a subepithelial lesion by size, location, layer of origin, echogenicity and shape. EUS alone does not distinguish all types (Deprez et al. 2022).
- Indication for tissue. ESGE suggests tissue diagnosis for subepithelial lesions with features of gastrointestinal stromal tumor (GIST) that are larger than 20 mm, have high-risk stigmata, or require surgical resection or oncologic treatment (Deprez et al. 2022).
- Method. ESGE recommends EUS-guided fine-needle biopsy or mucosal incision-assisted biopsy (MIAB) equally for lesions of 20 mm or more (Deprez et al. 2022). The 2025 ESGE review adds that MIAB could be the first choice for lesions smaller than 20 mm when expertise is available (Facciorusso et al. 2025).
EBUS-TBNA technique and specimen acquisition
CHEST guideline on EBUS-TBNA sample acquisition and handling
For patients with suspected malignancy, the CHEST guideline on acquisition and handling of EBUS-TBNA samples (published online 2024) makes the following recommendations (Gilbert et al. 2025; American College of Chest Physicians 2024):
| Topic | Statement | Strength |
|---|---|---|
| Number of passes | Four or more needle passes over three or fewer | Strong recommendation |
| Needle size | 21G or 22G over 19G | Conditional recommendation |
Studies of EBUS-TBNA passes and suction
Passes without on-site evaluation. In 163 lymph node stations sampled four times each without on-site evaluation, adequacy was 90.1% after one aspiration and 100% after three. Sensitivity for malignancy was 69.8%, 83.7%, 95.3% and 95.3% after one, two, three and four aspirations. When a tissue core was obtained in the first or second aspiration, two aspirations gave a sensitivity of 91.9% (Lee et al. 2008).
Suction. In a randomized trial of 115 patients and 192 lymph nodes, sampling with and without suction gave the same adequacy (88% and 88%). Diagnostic and sample-quality concordance between the methods was high regardless of node size (Casal et al. 2012).
Serious adverse events. In a systematic review of 16,181 patients, serious adverse events followed 0.05% of EBUS procedures and 0.30% of EUS procedures for mediastinal and hilar nodes or central lung lesions. No deaths were reported (von Bartheld et al. 2014).
Mediastinal and hilar lymph node stations reached by EBUS and EUS
The International Association for the Study of Lung Cancer (IASLC) lymph node map gives anatomic definitions for every nodal station and groups stations into zones (Rusch et al. 2009). The 2015 ESGE/ERS/ESTS guideline on combined endosonography describes which stations each method reaches (Vilmann et al. 2015).
| IASLC station | EBUS-TBNA | EUS(-B)-FNA |
|---|---|---|
| 2R and 4R (right paratracheal) | Accessible | Difficult to reach; large nodes over 2 cm may be sampled |
| 2L and 4L (left paratracheal) | Accessible | Accessible |
| 5 and 6 (aortopulmonary and para-aortic) | Not accessible | Visualized but rarely sampled without traversing the pulmonary artery or aorta |
| 7 (subcarinal) | Accessible | Accessible |
| 8 and 9 (paraesophageal and pulmonary ligament) | Not accessible | Accessible |
| 10 (hilar) and 11–12 (intrapulmonary) | Accessible | Not accessible |
Source: Vilmann et al. 2015.
- Stations 5 and 6. Surgical staging by video-assisted thoracoscopic surgery is the method of choice for these stations (Vilmann et al. 2015).
- Sites below the diaphragm. EUS-FNA also reaches retroperitoneal nodes near the aorta and celiac trunk, the left lobe of the liver and the left adrenal gland. For a left adrenal gland suspected of metastasis, the guideline suggests EUS-FNA (grade C) (Vilmann et al. 2015).
- Stations sampled for staging in 2015. For an abnormal mediastinum on CT or PET-CT, the 2015 guideline suggested a complete assessment and sampling of at least three mediastinal stations (4R, 4L and 7). A node was regarded as suspicious when its short axis exceeded 10 mm or it was FDG-avid (Vilmann et al. 2015). The 2026 ERS/ESGE/ESTS recommendations for systematic staging are given in Lung FNA Adequacy and Rapid On-Site Evaluation.
- Pooled sensitivity. The 2015 guideline cites meta-analyses with pooled sensitivities of 93% for EBUS-TBNA, 83% for EUS-FNA and 86% for the combined approach (Vilmann et al. 2015).
Adequacy criteria for EBUS-TBNA lymph node samples and the role of EBUS-TBNA in mediastinal staging are covered in Lung FNA Adequacy and Rapid On-Site Evaluation.
Peripheral bronchoscopy: radial EBUS, electromagnetic navigation and robotic bronchoscopy
Yield of conventional and guided bronchoscopy for peripheral lesions
- Conventional bronchoscopy. Flexible bronchoscopy had a sensitivity of 88% for central endobronchial lung cancer. For peripheral lesions, sensitivity was 34% for lesions smaller than 2 cm and 63% for lesions larger than 2 cm (Rivera et al. 2013).
- Radial-probe EBUS. In 16 studies (1,420 patients), radial EBUS had a point sensitivity of 0.73 and a point specificity of 1.00 for lung cancer. Sensitivity varied with lesion size and with the prevalence of malignancy (Steinfort et al. 2011).
- Electromagnetic navigation. In 15 studies (1,033 nodules), ENB gave a definitive diagnosis in 64.9% of procedures, and sensitivity for cancer was 71.1%. Pneumothorax occurred in 3.1% of patients, and 1.6% required chest tube drainage (Gex et al. 2014).
- Factors associated with higher ENB yield. Upper or middle lobe location, larger nodule size, lower registration error, a bronchus sign on CT, combined use of a radial probe, and catheter suction as a sampling technique were associated with higher yield. Studies using general anesthesia or ROSE reported better yields (Gex et al. 2014).
The NAVIGATE study of electromagnetic navigation bronchoscopy
NAVIGATE enrolled 1,215 subjects at 29 US academic and community sites. The median lesion size was 20 mm. Fluoroscopy was used in 91% of cases and radial EBUS in 57% (Folch et al. 2019).
- Yield. The 12-month diagnostic yield was 73%. Sensitivity for malignancy was 69% and negative predictive value 56% (Folch et al. 2019).
- Safety. Grade 2 or higher pneumothorax occurred in 2.9%, grade 2 or higher bronchopulmonary hemorrhage in 1.5% and grade 4 or higher respiratory failure in 0.7% (Folch et al. 2019).
Robotic-assisted bronchoscopy
- Cadaver comparison. In a randomized cadaver study of nodules smaller than 2 cm, robotic bronchoscopy localized and punctured the target in 80% of attempts. Electromagnetic navigation did so in 45% (P = .02) (Yarmus et al. 2020).
- Meta-analysis. In 10 studies (725 lesions), the pooled diagnostic yield of robotic bronchoscopy was 80.4%. Lesions larger than 30 mm, a bronchus sign and a concentric radial EBUS view were associated with higher yield. Studies that used cryoprobes reported 90.0% yield. The pooled complication rate was 3.0%, and pneumothorax was the most common complication at 1.8% (Zhang et al. 2024).
- PRECIsE study. In 305 procedures with shape-sensing robotic bronchoscopy at 6 centers, the median nodule size was 17 mm. Sensitivity for malignancy at 2 years was 81.3%. Diagnostic yield was 74.1% by the strict ATS/ACCP definition and 77.5% by the intermediate definition. Pneumothorax requiring intervention occurred in 1.6% and bleeding in 1.0% (Ost et al. 2026).
- Robotic bronchoscopy compared with CT-guided biopsy. Five retrospective studies from one US health system compared the two approaches directly. Diagnostic yield did not differ (risk ratio 0.99). Pneumothorax requiring a chest tube or admission was less frequent with robotic bronchoscopy (risk ratio 0.25). The authors graded the certainty of the evidence as low to very low (Hassan et al. 2026).
| Method | Diagnostic yield or sensitivity | Pneumothorax | Source |
|---|---|---|---|
| CT-guided TTNA | Pooled sensitivity 90% | 18.8% (FNA) | Rivera et al. 2013; Heerink et al. 2017 |
| Radial-probe EBUS | Sensitivity 0.73 | Not pooled in the meta-analysis | Steinfort et al. 2011 |
| Electromagnetic navigation | Definitive diagnosis 64.9% | 3.1% | Gex et al. 2014 |
| Electromagnetic navigation (NAVIGATE) | 12-month yield 73% | 2.9% grade 2 or higher | Folch et al. 2019 |
| Robotic bronchoscopy (meta-analysis) | Pooled yield 80.4% | 1.8% | Zhang et al. 2024 |
| Shape-sensing robotic bronchoscopy (PRECIsE) | Strict yield 74.1% | 1.6% requiring intervention | Ost et al. 2026 |
Strict definition of diagnostic yield for peripheral lung sampling
An official ATS/ACCP research statement of 2024 defined diagnostic yield for studies of advanced bronchoscopy (Gonzalez et al. 2024).
- Numerator. Patients in whom the procedure establishes a specific benign or malignant diagnosis sufficient to inform patient care (Gonzalez et al. 2024).
- Denominator. All patients in whom the procedure was attempted or performed (Gonzalez et al. 2024).
- Follow-up. Clinical or radiographic follow-up may be part of the reference standard. It is not used to calculate diagnostic yield from the procedural encounter (Gonzalez et al. 2024).
- Intermediate definition. An intermediate definition counts nonspecific benign results that prove nonmalignant on follow-up. The statement recommends against intermediate and liberal definitions (Gonzalez et al. 2024).
| Procedural result | Classification under the strict definition |
|---|---|
| Non-small cell carcinoma, adenocarcinoma, squamous cell carcinoma, small cell carcinoma, metastatic carcinoma, typical or atypical carcinoid | Diagnostic (specific malignant) |
| Hamartoma, lipoma, papilloma, organizing pneumonia, fungal or mycobacterial infection, granulomatous inflammation | Diagnostic (specific benign) |
| Atypia or suspicious cells | Nondiagnostic |
| Nonspecific inflammation | Nondiagnostic |
| Blood, necrosis, normal lung parenchyma or insufficient tissue | Nondiagnostic |
Source: Gonzalez et al. 2024.
Sources of error in interpreting image-guided samples
| Situation | Error | Correct interpretation |
|---|---|---|
| Nonspecific inflammation on a navigational biopsy of a nodule that later resolves | Counted as a diagnostic procedure | Nondiagnostic under the strict definition (Gonzalez et al. 2024) |
| Atypical cells on a peripheral lung sample | Counted as diagnostic | Nondiagnostic under the strict definition (Gonzalez et al. 2024) |
| Thyroid nodule nondiagnostic twice by palpation | Repeated by palpation | Ultrasound guidance lowers the inadequate rate (Danese et al. 1998; Conrad et al. 2018) |
| EBUS-TBNA of a node in suspected malignancy with three passes | Sampling regarded as complete | Four or more passes recommended (Gilbert et al. 2025) |
| Subepithelial gastric lesion of 25 mm with GIST features | Sampled with forceps biopsy alone | EUS-FNB or MIAB recommended (Deprez et al. 2022) |
| EUS-guided sampling of a solid mass | Evaluation of smears alone | Histologic preparations suggested in addition to smears (Polkowski et al. 2017) |
Rapid On-Site Evaluation, Telecytology and Core Needle Touch Imprints
Definition. Rapid on-site evaluation (ROSE) is a service provided by cytologists at the time of a fine-needle aspiration (FNA) or needle biopsy. It confirms specimen adequacy and triages material for ancillary testing (VanderLaan et al. 2019). Telecytology applied to ROSE transmits images of the slides to a pathologist at another location. It can increase productivity, reduce costs and provide subspecialty expertise where access to a cytopathologist is limited (Lin et al. 2024). A touch preparation (touch imprint) is a slide made by touching or rolling a core needle biopsy on glass. It allows ROSE of small tissue samples such as core needle biopsies (Satturwar et al. 2020).
Related page: Lung FNA Adequacy and Rapid On-Site Evaluation (ROSE and adequacy criteria for lung and EBUS-TBNA samples) Related page: Normal pancreas, gastrointestinal contaminants and EUS-guided sampling (ROSE and needle choice for EUS sampling of the pancreas)
Society recommendations on rapid on-site evaluation
- British Society for Clinical Cytology. The best results are obtained when a pathologist or a trained biomedical scientist (cytotechnologist) provides immediate on-site assessment of adequacy, whether or not the FNA requires image guidance (Kocjan et al. 2009).
- ESGE 2017. EUS-guided sampling is recommended equally with or without on-site cytologic evaluation (Polkowski et al. 2017).
- CHEST guideline on EBUS-TBNA samples. For suspected malignancy, ROSE is suggested over usual care as a conditional recommendation (Gilbert et al. 2025; American College of Chest Physicians 2024).
Practice patterns of rapid on-site evaluation in the United States
| Survey finding | 2019 American Society of Cytopathology (ASC) survey | 2025 ASC survey |
|---|---|---|
| Respondents | 541 (255 pathologists, 261 cytotechnologists, 19 trainees, 6 others) | 280 per question (60.3% cytologists or supervisors, 35.2% pathologists or directors) |
| ROSE offered or performed | 95.4% | 96.1% |
| Telecytology used for ROSE | 21.9% | 43.1% |
| Personnel | Cytotechnologists involved in most practices | Both cytologist and pathologist 45.5%; cytologist only 33.2% |
| Other findings | EBUS-TBNA was the procedure most often using ROSE; about 70% of ROSE procedures required more than 30 minutes of cytologist time | Mistimed calls to cytology 71.4%; inadequate clinical information 55.2%; space constraints 63.6%; passes already taken before arrival 44.9% |
Sources: VanderLaan et al. 2019; Goyal et al. 2026.
- Attitudes. Respondents to the 2019 survey viewed ROSE as valuable. They reported staffing, time commitment and inadequate reimbursement as challenges and thought telecytology could alleviate some of them (Sauter et al. 2020).
Effect of rapid on-site evaluation on adequacy and diagnostic yield
The benefit of ROSE depends on the adequacy achieved without it.
| Study | Design | Main result |
|---|---|---|
| Schmidt et al. 2013 | Meta-analysis of head-to-head comparisons, EUS-FNA of pancreatic lesions | Adequacy improved by an average of 10% (95% CI 5–24%); no effect on diagnostic yield; benefit at sites with per-case adequacy below 90% |
| Matynia et al. 2014 | Meta-analysis of 70 studies, EUS-FNA of solid pancreatic lesions | Overall adequacy 96.2%; ROSE improved adequacy by up to 3.5%; assessor type had no effect |
| Hébert-Magee et al. 2013 | Meta-analysis of 34 studies (3,644 patients), EUS-FNA for pancreatic ductal adenocarcinoma | Pooled sensitivity 88.6%, specificity 99.3%; ROSE remained a significant determinant of accuracy |
| Wani et al. 2015 | Randomized trial, 241 patients, EUS-FNA of pancreatic masses | With and without ROSE: diagnostic yield of malignancy 75.2% and 71.6%; inadequate specimens 9.8% and 13.3% (neither difference significant); median passes 4 with ROSE, against 7 passes fixed by protocol without it |
| Oki et al. 2013 | Randomized trial, 108 analyzed patients, EBUS-TBNA for suspected lung cancer | With and without ROSE: mean punctures 2.2 and 3.1; additional procedures 11% and 57%; sensitivity 88% and 86%; bronchoscopy time 22.3 and 22.1 minutes |
| Koç et al. 2026 | Before-and-after study, 916 thyroid FNAs, cytologist-performed ROSE | Adequacy 49.2% before and 85.8% after; Bethesda category I 50.4% and 14.8%; passes 3.27 and 2.12; repeat cytology 8.8% and 5.2% |
- Wani trial costs and safety. Procedure time, adverse events, repeat procedures, costs and accuracy did not differ between arms (Wani et al. 2015).
- Wani trial design. The number of passes in the ROSE arm was set by the on-site cytopathologist. Seven passes were performed in the arm without on-site evaluation (Wani et al. 2015).
- Thyroid ROSE. The improvement in the nondiagnostic rate after ROSE is related to the rate before ROSE and is greatest for less experienced aspirators. ROSE prolongs the procedure, requires resources and adds cost (Michael et al. 2020).
- Cytologist training in the Koç study. The cytologist completed a structured 3-month training program under a pathologist before performing ROSE (Koç et al. 2026).
Allocation of FNA material for ancillary studies
The CAP-led guideline on thoracic small biopsy and cytology specimens contains 16 statements. It concludes that core needle and fine-needle techniques provide cytologic and histologic material for ancillary studies, and that ROSE remains helpful in triage, handling and processing (Roy-Chowdhuri et al. 2020). The media and passes for flow cytometry, cultures and molecular testing of lymph nodes are covered in Lymph Node FNA Triage for Flow Cytometry, Cultures and Molecular Testing, and collection media for all specimen types in Cytology Specimen Types and Triage.
- Dedicated passes in lung carcinoma. The allocation of passes for ancillary studies is covered in Lung FNA Adequacy and Rapid On-Site Evaluation.
- Touch preparations. An additional untouched core is requested so that tumor cells remain for ancillary testing. At least 3 unstained touch preparations are recommended for possible FISH (Satturwar et al. 2020).
Ancillary tests on the FNA needle rinse
After smears are made, the material left in the needle and hub can be rinsed into a medium.
| Study | Rinse and medium | Test | Result |
|---|---|---|---|
| Ko et al. 2019 | EBUS-TBNA needle rinse, 4,672 patients | Acid-fast bacilli culture and MTB PCR | Adding culture raised the diagnosis of tuberculous lymphadenitis from 0.2% to 1.0% in suspected lung cancer, from 1.0% to 4.4% in extrapulmonary malignancy and from 4.5% to 10.3% in benign disease; PCR increased the yield only in benign disease (8.8%) |
| Akinsanya et al. 2026 | FNA supernatant in CytoRich Red, 10% formalin or 10% bovine serum albumin, 31 lung carcinomas | Real-time PCR for KRAS and EGFR | CytoRich Red: 11 of 11 concordant with controls; formalin: 6 of 12 needed repeat extraction and 1 remained invalid; albumin: 3 of 8 failed |
| Nacchio et al. 2026 | FNA rinse in nuclease-free water, 34 metastatic melanomas | Cell-free DNA for BRAF and NRAS | All rinses evaluable; 26.5% of cell blocks sufficient; one discordant case, BRAF detected only in the rinse |
- Routine culture of EBUS rinses. Routine acid-fast culture of the needle rinse increased the yield for tuberculous lymphadenitis in all patient groups in an intermediate-burden country (Ko et al. 2019).
- Preservation of the cell block. FNA supernatant and rinse cell-free DNA allow mutation testing while the cell block is kept for other studies (Akinsanya et al. 2026; Nacchio et al. 2026).
- Collection medium. In the supernatant study, the medium affected the success of DNA extraction and PCR. Formalin and bovine serum albumin performed worse than CytoRich Red (Akinsanya et al. 2026).
Medicare coding rules for the immediate adequacy assessment
The Medicare National Correct Coding Initiative (NCCI) Policy Manual defines the unit of service for the adequacy assessment codes (CMS NCCI Policy Manual, Chapter X, 2026).
- Codes. CPT 88172 describes the immediate cytohistologic study of a fine-needle aspirate to determine adequacy, first evaluation episode, each site. CPT 88177 describes each separate additional evaluation episode at the same site.
- Evaluation episode. An evaluation episode is the examination of a set of cytologic material to determine whether it is adequate for diagnosis. It ends when the pathologist advises the operating physician whether the material is adequate. It is independent of the number of needle passes and the number of slides.
- Additional episode. An additional episode (88177) begins only after the pathologist has rendered an assessment and the operating physician has used it to decide whether to make more passes.
- Continuous sampling. When the operating physician makes multiple passes while the pathologist examines each pass as rapidly as possible, only one evaluation episode is reported, because the operator does not wait for the result.
- Separate lesions. 88172 may be reported with one unit for each separate lesion evaluated.
- Pathologist assessment. The evaluation episode ends when a pathologist renders the adequacy assessment to the operating physician (CMS NCCI Policy Manual, Chapter X, 2026). CPT 88172, 88177, 88333 and 88334 apply only when a cytopathologist performs the immediate assessment while the patient is in the procedure room (Krishnamurthy 2025).
| Scenario at one lesion | Codes reported |
|---|---|
| Three passes examined as they arrive; operator continues without waiting; adequacy reported once at the end | 88172 × 1 |
| First set reported inadequate; operator waits, makes further passes, and the new material is assessed | 88172 × 1 and 88177 × 1 |
| Two separate lesions each assessed once | 88172 × 2 (one per lesion) |
Source: CMS NCCI Policy Manual, Chapter X, 2026.
- Interpretation code. CPT 88173 is the interpretation and report of the fine-needle aspirate. Its digitization add-on is 0837T. 0835T (with 88172) and 0836T (with 88177) are not reported when 0837T is reported with 88173 (CAP 2024).
- Touch preparations. CPT 88333 and 88334 describe pathology consultation during surgery, cytologic examination (for example, touch or squash preparation), initial site and each additional site (CAP 2024; CMS NCCI Policy Manual, Chapter X, 2026). They are the codes applied to touch preparations at ROSE (Krishnamurthy 2025).
Telecytology for rapid on-site evaluation
Telecytology platforms
| Platform | Description | Advantages | Limitations |
|---|---|---|---|
| Static camera images | A microscope camera sends still images by e-mail, smartphone application, secure cloud or screen sharing | Low cost (about $5,000); suitable for low volume and as backup | Image selection depends on the operator; resolution less than optimal; time to send images |
| Live video streaming | A high-definition camera streams microscope images behind the institutional firewall | Real-time view of the whole smear; several viewers; about $12,000–$45,000 | The on-site operator must move the slide skillfully |
| Robotic microscope | Remote control of a microscope with a video camera | Remote navigation; operator skill not required; about $60,000–$85,000 | Slight lag in live view |
| Digital microscope with whole-slide scanner | Live view or whole-slide imaging | Remote navigation; about $30,000–$55,000 | Whole-slide imaging takes at least 2–3 minutes per slide |
Source: Krishnamurthy 2025.
Validation of telecytology for ROSE
The ASC published validation recommendations for telecytology used in ROSE (Lin et al. 2024).
Systems. All hardware and software are tested separately and as a whole.
People. Everyone who takes part is trained and receives regular competency evaluation.
Case sets. Retrospective slides with defined diagnoses are used for validation, and prospective cases for verification and quality assurance.
Quality management. Telecytology is integrated into the laboratory quality management system. Benchmarks for discrepancy between preliminary and final diagnoses are set and monitored.
Downgrades. Discrepancies that downgrade malignant cases to benign receive special attention.
CAP whole-slide imaging guideline, 2022. The guideline covers frozen sections, surgical specimens and hematopathology and excludes cytology. It specifies at least 60 cases, intraobserver concordance and a 2-week washout, with concern if concordance is below 95% (Evans et al. 2022).
Staged deployment with trainee operators. One institution installed dynamic telecytology in high-volume radiology suites and validated it with retrospective and prospective cases. Cytopathology fellows operated the system in 71.6% of 120 cases and cytotechnologists in 28.3%. Adequacy concordance with the final diagnosis was 100% in retrospective and 98.5% in prospective cases. In prospective cases, concordance for malignancy was 93.3% and the downgrade rate 2.7% (Sarode et al. 2021).
Accuracy of telecytology-assisted ROSE
| Study | Setting | Result |
|---|---|---|
| Alhamar et al. 2025 | 70,612 telecytology ROSE cases of FNA and core touch preparations over 7 years | Reported as adequate on site but nondiagnostic at final review in 0.06%; misinterpretation of benign or reactive cells as neoplastic caused 76.2%; highest rate in kidney (0.90%) |
| Udoh et al. 2026 | 1,697 FNAs with ROSE at three campuses | Major discrepancies in 3% of in-person ROSE and 5% of telecytology ROSE (P = 0.2429); in-person ROSE more accurate for lymph node, head and neck, and bone and soft tissue |
| Perez et al. 2021 | 186 touch imprints of core biopsies by dynamic telecytology | 87% concordant; sensitivity 87.9%, specificity 95.7%; causes of discordance included interpretive error and sampling |
| Khurana et al. 2013 | 200 EBUS-TBNAs, 100 by camera telecytology and 100 by conventional microscopy | Concordance of preliminary and final diagnoses 96% with telecytology and 93% with microscopy; unsatisfactory at ROSE 4% and 2% |
| Khurana et al. 2015 | 116 ultrasound-guided FNAs of nonthyroid head and neck lesions, 58 by each method | Concordance 94.8% with telecytology and 98.3% with microscopy (P = 0.309); no unsatisfactory cases |
| Lucà et al. 2025 | 50 CT-guided lung core touch imprints, remote-controlled microscope | 86% diagnostic; 100% concordance between remote and on-site ROSE; about 3 minutes per case |
- Telecytology-specific problems. Survey respondents reported difficulty visualizing crowded cell groups and failure of the on-site individual to show diagnostic cells to the remote pathologist (Goyal et al. 2026).
- Causes of discordance in the Khurana studies. Discordance arose from distinguishing small cell carcinoma from reactive lymph node with crush artifact, from atypia of reactive bronchial cells, and from cell block, Papanicolaou-stained slides or flow cytometry results available only at final sign-out (Khurana et al. 2013; Khurana et al. 2015).
Coding for slide digitization during telecytology
- Category III add-on codes. Digitization add-on codes became effective on January 1, 2024. 0835T accompanies 88172, and 0836T accompanies 88177. 0843T and 0844T accompany 88333 and 88334 for touch and squash preparations. Each add-on is reported one-to-one with its primary pathology code (CAP 2024).
- Payment. The add-on codes had not been assigned national pricing in 2025, and insurers did not reimburse the technical charges of telecytology ROSE (Krishnamurthy 2025).
Touch imprints of core needle biopsies
Indications and technique of core needle touch imprints
- Indications. Touch preparations suit cellular, nonsclerotic lesions and are not optimal for cystic lesions. Hematolymphoid neoplasms, small round blue cell tumors and bone specimens benefit most (Satturwar et al. 2020).
- Sequence. FNA is often performed first to confirm targeting, and the touch preparation follows (Satturwar et al. 2020).
- Method. The core is touched along the short axis of an uncoated, unfrosted slide, once or twice. A core is not dragged more than 1 cm. Delicate cores are handled by touch-and-pick, and firm cores such as bone are rolled. Forceps can crush cells (Satturwar et al. 2020).
Depletion of core cellularity by vigorous touch preparations
Ex vivo cores (n = 56) from resected lung and kidney tumors were subjected to four touch-preparation methods (Rekhtman et al. 2015).
| Method | Cellularity of the touch preparation, % of core | DNA in the touch preparation, % of core |
|---|---|---|
| Imprint only | 19% | 15% |
| 1-cm drag | 33% | 36% |
| 2-cm drag | 41% | 50% |
| Full-slide drag | 46% | Not measured |
Source: Rekhtman et al. 2015. Diagnostic accuracy was not inferior for the less extensive preparations. The authors advised avoiding forceful touch preparations and obtaining additional samples for ancillary studies when feasible.
Diagnostic accuracy of touch imprints
- Mixed sites. In 252 core biopsies of liver, lung, lymph node, bone and soft tissue, imprint cytology had a sensitivity of 96%, a specificity of 74% and an accuracy of 91%. Correlation was 91% in malignant cases and 59% in benign cases (Kubik et al. 2015).
- Bone. In 61 bone core biopsies, on-site imprint evaluation diagnosed 86% of malignancies and 13% of benign lesions. On-site evaluation was nonspecific or nondiagnostic in 54% of cases (Kubik et al. 2014).
- Breast. In 79 breast core biopsies with satisfactory imprints, sensitivity was 86.05%, specificity 97.22% and accuracy 90% (Boler et al. 2024).
Cytomorphology of touch preparations compared with aspirate smears
| Feature | Touch preparation | Aspirate smear | Core biopsy |
|---|---|---|---|
| Architecture | Disrupted | Disrupted | Intact |
| Cohesive groups | Without surrounding stroma | Without surrounding stroma | With stroma |
| Stroma | None to scant | None to scant | Usually present |
| Blood | Limited dilution | Often present | Usually absent |
Source: Satturwar et al. 2020.
Background. The background of a touch preparation is variable and may be patchy or absent. Lymphoglandular bodies may be absent because cells are imprinted intact (Satturwar et al. 2020).
Tigroid background. A tigroid background does not form without smearing. Its absence on a touch preparation therefore does not exclude Ewing sarcoma (Satturwar et al. 2020).
Endothelial wrapping. Endothelial wrapping is scant to absent in touch preparations of hepatocellular carcinoma (Satturwar et al. 2020).
Artifacts. Touch preparations show streaking, thick areas and stripped cells. Aspirate smears show air-drying artifact, crushed cells and obscuring material (Satturwar et al. 2020).
Interpretive errors on touch preparations. Streaking is common when cores are dragged, especially in lymphoid lesions and small cell carcinoma. Reed-Sternberg cells of classic Hodgkin lymphoma may cluster and mimic carcinoma. Megakaryocytes and reactive osteoblasts in bone imprints can be mistaken for malignant cells (Satturwar et al. 2020).
Ancillary testing. Unstained touch preparations contain whole nuclei and are suitable for fluorescence in situ hybridization (FISH). At least 3 unstained slides are recommended (Satturwar et al. 2020).
Sources of error in ROSE, telecytology and touch imprints
| Error | Consequence | Correct practice |
|---|---|---|
| Reporting 88177 for passes examined while the operator continued without waiting | Coding error | One evaluation episode (88172) (CMS NCCI Policy Manual, Chapter X, 2026) |
| Interpretation of reactive or nonneoplastic cells as neoplastic on telecytology | Specimen reported as adequate and later found nondiagnostic | Attention to site-specific sources of error, especially in kidney (Alhamar et al. 2025) |
| Remote pathologist shown only selected fields | Missed diagnostic cells | Operator training and platforms with remote navigation (Goyal et al. 2026; Krishnamurthy 2025) |
| Full-slide drag of a lung core | 46% of core cellularity transferred to the slide; a 2-cm drag transfers 50% of core DNA | Imprint or a drag of 1 cm or less; additional core for ancillary tests (Rekhtman et al. 2015; Satturwar et al. 2020) |
| Applying the CAP whole-slide imaging validation guideline to cytology | Validation outside the guideline scope | ASC telecytology recommendations (Evans et al. 2022; Lin et al. 2024) |
References
- Ahn SY, Yoon SH, Yang BR, Kim YT, Park CM, Goo JM. Risk of pleural recurrence after percutaneous transthoracic needle biopsy in stage I non-small-cell lung cancer. Eur Radiol. 2019;29(1):270–278. doi:10.1007/s00330-018-5561-5. PMID 29948086
- Akinsanya A, Gorden R, Rector M, et al. Utility of fine needle aspiration supernatant for real-time PCR-based mutation analysis in non-small cell lung cancer. Diagn Cytopathol. 2026;54(11):805–811. doi:10.1002/dc.70184. PMID 42464567
- Alhamar M, Rudomina D, Wang L, et al. Rapid on-site evaluation using telecytology: quality assurance study at a high-volume cancer center. Cancer Cytopathol. 2025;133(1):e22929. doi:10.1002/cncy.22929. PMID 39745134
- American College of Chest Physicians. EBUS transbronchial needle samples [guideline summary page]. 2024. https://www.chestnet.org/guidelines-and-topic-collections/guidelines/interventional-pulmonary/ebus-transbronchial-needle-samples
- Baloch ZW, Cibas ES, Clark DP, et al. The National Cancer Institute Thyroid fine needle aspiration state of the science conference: a summation. Cytojournal. 2008;5:6. doi:10.1186/1742-6413-5-6. PMID 18394201
- Berger-Richardson D, Swallow CJ. Needle tract seeding after percutaneous biopsy of sarcoma: risk/benefit considerations. Cancer. 2017;123(4):560–567. doi:10.1002/cncr.30370. PMID 27859013
- Boler AK, Roy S, Singh PP, Maiti B. Effectivity of touch imprint cytology of core needle biopsy in evaluation of breast lesions: a study in changing trends of rapid on site evaluation. J Cytol. 2024;41(3):162–165. doi:10.4103/joc.joc_167_22. PMID 39239316
- Brugge WR, De Witt J, Klapman JB, et al. Techniques for cytologic sampling of pancreatic and bile duct lesions: the Papanicolaou Society of Cytopathology guidelines. Cytojournal. 2014;11(Suppl 1):2. doi:10.4103/1742-6413.133311. PMID 25191516
- Casal RF, Staerkel GA, Ost D, et al. Randomized clinical trial of endobronchial ultrasound needle biopsy with and without aspiration. Chest. 2012;142(3):568–573. doi:10.1378/chest.11-0692. PMID 22156610
- Centers for Medicare & Medicaid Services. National Correct Coding Initiative Policy Manual for Medicare Services, Chapter III (Surgery: Integumentary System), revision date 1/1/2026. https://www.cms.gov/files/document/03-chapter3-ncci-medicare-policy-manual-2026-final.pdf
- Centers for Medicare & Medicaid Services. Medicare program; revisions to payment policies under the physician fee schedule and other revisions to Part B for CY 2019 (final rule). Fed Regist. 2018;83(226):59452–60303 (fine needle aspiration, pp. 59517–59518). https://www.govinfo.gov/content/pkg/FR-2018-11-23/html/2018-24170.htm
- Chen QY, Zhang T, Li WG, et al. Comparison of cytological adequacy in ultrasound-guided fine-needle aspiration of thyroid nodules with different numbers of needle passes. Eur Rev Med Pharmacol Sci. 2023;27(13):6000–6005. doi:10.26355/eurrev_202307_32952. PMID 37458636
- College of American Pathologists. Digital pathology codes (Category III add-on codes effective January 1, 2024). https://www.cap.org/advocacy/payment-and-reimbursement-policy/digital-pathology-codes/
- Conrad R, Yang SE, Chang S, et al. Comparison of cytopathologist-performed ultrasound-guided fine-needle aspiration with cytopathologist-performed palpation-guided fine-needle aspiration: a single institutional experience. Arch Pathol Lab Med. 2018;142(10):1260–1267. doi:10.5858/arpa.2017-0123-OA. PMID 29697276
- Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A. Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid. 1998;8(1):15–21. doi:10.1089/thy.1998.8.15. PMID 9492148
- Deprez PH, Moons LMG, O'Toole D, et al. Endoscopic management of subepithelial lesions including neuroendocrine neoplasms: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2022;54(4):412–429. doi:10.1055/a-1751-5742. PMID 35180797
- Evans AJ, Brown RW, Bui MM, et al. Validating whole slide imaging systems for diagnostic purposes in pathology. Arch Pathol Lab Med. 2022;146(4):440–450. doi:10.5858/arpa.2020-0723-CP. PMID 34003251
- Facciorusso A, Arvanitakis M, Crinò SF, et al. Endoscopic ultrasound-guided tissue sampling: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review. Endoscopy. 2025;57(4):390–418. doi:10.1055/a-2524-2596. PMID 40015316
- Folch EE, Pritchett MA, Nead MA, et al. Electromagnetic navigation bronchoscopy for peripheral pulmonary lesions: one-year results of the prospective, multicenter NAVIGATE study. J Thorac Oncol. 2019;14(3):445–458. doi:10.1016/j.jtho.2018.11.013. PMID 30476574
- Fornari F, Civardi G, Cavanna L, et al. Complications of ultrasonically guided fine-needle abdominal biopsy. Results of a multicenter Italian study and review of the literature. Scand J Gastroenterol. 1989;24(8):949–955. doi:10.3109/00365528909089239. PMID 2688068
- Gex G, Pralong JA, Combescure C, et al. Diagnostic yield and safety of electromagnetic navigation bronchoscopy for lung nodules: a systematic review and meta-analysis. Respiration. 2014;87(2):165–176. doi:10.1159/000355710. PMID 24401166
- Gilbert CR, Dust C, Argento AC, et al. Acquisition and handling of endobronchial ultrasound transbronchial needle samples: an American College of Chest Physicians clinical practice guideline. Chest. 2025;167(3):899–909. doi:10.1016/j.chest.2024.08.056. PMID 39343294
- Gonzalez AV, Silvestri GA, Korevaar DA, et al. Assessment of advanced diagnostic bronchoscopy outcomes for peripheral lung lesions: a Delphi consensus definition of diagnostic yield and recommendations for patient-centered study designs. An official American Thoracic Society/American College of Chest Physicians research statement. Am J Respir Crit Care Med. 2024;209(6):634–646. doi:10.1164/rccm.202401-0192ST. PMID 38394646
- Goyal A, Alperstein SA, Robila V, et al. Interdisciplinary and inter-personnel issues during rapid on-site evaluation: an analysis of 2025 American Society of Cytopathology survey results. J Am Soc Cytopathol. 2026 (online ahead of print). doi:10.1016/j.jasc.2026.09.001. PMID 42897077
- Guidelines of the Papanicolaou Society of Cytopathology for fine-needle aspiration procedure and reporting. The Papanicolaou Society of Cytopathology Task Force on Standards of Practice. Mod Pathol. 1997;10(7):739–747. PMID 9237187. Also published in Diagn Cytopathol. 1997;17(4):239–247. doi:10.1002/(sici)1097-0339(199710)17:4<239::aid-dc1>3.0.co;2-7. PMID 9316777
- Harper K, Hurrell C, Gupta A, et al. CAR/CAIR practice guidelines: periprocedural management of patient bleeding risk. Can Assoc Radiol J. 2026;77(4):637–650. doi:10.1177/08465371261433905. PMID 41964243
- Hassan AA, El Sheikh MM, Hassan AA, et al. Robotic-assisted transbronchial biopsy versus computed tomography-guided transthoracic needle biopsy for peripheral pulmonary lesions: a systematic review and meta-analysis of direct comparative studies. J Robot Surg. 2026;20(1):955. doi:10.1007/s11701-026-03867-8. PMID 42696224
- Hébert-Magee S, Bae S, Varadarajulu S, et al. The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound-guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis. Cytopathology. 2013;24(3):159–171. doi:10.1111/cyt.12071. PMID 23711182
- Heerink WJ, de Bock GH, de Jonge GJ, Groen HJ, Vliegenthart R, Oudkerk M. Complication rates of CT-guided transthoracic lung biopsy: meta-analysis. Eur Radiol. 2017;27(1):138–148. doi:10.1007/s00330-016-4357-8. PMID 27108299
- Khadra H, Kholmatov R, Monlezun D, Kandil E. Do anticoagulation medications increase the risk of haematoma in ultrasound-guided fine needle aspiration of thyroid lesions? Cytopathology. 2018;29(6):565–568. doi:10.1111/cyt.12608. PMID 29969159
- Khurana KK, Kovalovsky A, Wang D, Lenox R. Feasibility of dynamic telecytopathology for rapid on-site evaluation of endobronchial ultrasound-guided transbronchial fine needle aspiration. Telemed J E Health. 2013;19(4):265–271. doi:10.1089/tmj.2012.0168. PMID 23540276
- Khurana KK, Xu W, Wang D, Swarnkar A. Rapid on-site evaluation with dynamic telecytopathology for ultrasound-guided fine-needle aspiration of head and neck nonthyroid lesions. J Pathol Inform. 2015;6:19. doi:10.4103/2153-3539.157781. PMID 26110087
- Ko RE, Jeong BH, Chon HR, et al. Clinical usefulness of routine AFB culture and MTB PCR of EBUS-TBNA needle rinse fluid. Respirology. 2019;24(7):667–674. doi:10.1111/resp.13488. PMID 30730098
- Koç T, Karabulut C, Kaya Ş, Şalk İ, Tuncer E. Impact of cytologist-performed rapid on-site evaluation on adequacy and diagnostic performance in thyroid fine needle aspiration cytology. Diagn Cytopathol. 2026 (online ahead of print). doi:10.1002/dc.70215. PMID 42808688
- Kocjan G, Chandra A, Cross P, et al. BSCC Code of Practice—fine needle aspiration cytology. Cytopathology. 2009;20(5):283–296. doi:10.1111/j.1365-2303.2009.00709.x. PMID 19754835
- Krishnamurthy S. Current landscape and emerging opportunities for using telecytology for rapid on-site assessment in cytopathology. Cancer Cytopathol. 2025;133(7):e70027. doi:10.1002/cncy.70027. PMID 40522771
- Kubik MJ, Bovbel A, Goli H, et al. Diagnostic value and accuracy of imprint cytology evaluation during image-guided core needle biopsies: review of our experience at a large academic center. Diagn Cytopathol. 2015;43(10):773–779. doi:10.1002/dc.23300. PMID 26119885
- Kubik MJ, Mohammadi A, Rosa M. Diagnostic benefits and cost-effectiveness of on-site imprint cytology adequacy evaluation of core needle biopsies of bone lesions. Diagn Cytopathol. 2014;42(6):506–513. doi:10.1002/dc.23065. PMID 24574374
- Kurtycz DFI, Baloch ZW, Balassanian R, Lynn T, Vohra P, Wu M. Pathologist performed ultrasound guided fine needle aspiration (US-FNA): current status, trends, and insights from the American Society of Cytopathology sponsored survey. J Am Soc Cytopathol. 2025;14(6):374–383. doi:10.1016/j.jasc.2025.05.001. PMID 40628593
- Lee HS, Lee GK, Lee HS, et al. Real-time endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal staging of non-small cell lung cancer: how many aspirations per target lymph node station? Chest. 2008;134(2):368–374. doi:10.1378/chest.07-2105. PMID 18263688
- Li H, Chen R, Zhao J. Correlation between percutaneous transthoracic needle biopsy and recurrence in stage I lung cancer: a systematic review and meta-analysis. BMC Pulm Med. 2020;20(1):198. doi:10.1186/s12890-020-01235-2. PMID 32689974
- Lin O, Alperstein S, Barkan GA, et al. American Society of Cytopathology telecytology validation recommendations for rapid on-site evaluation (ROSE). J Am Soc Cytopathol. 2024;13(2):111–121. doi:10.1016/j.jasc.2023.12.001. PMID 38310002
- Ljung BM, Drejet A, Chiampi N, et al. Diagnostic accuracy of fine-needle aspiration biopsy is determined by physician training in sampling technique. Cancer. 2001;93(4):263–268. doi:10.1002/cncr.9040. PMID 11507700
- Lucà S, Monti R, Della Corte CM, et al. Application of telepathology for rapid on-site evaluation of touch imprint cytology in CT-guided percutaneous transthoracic core needle biopsy of pulmonary nodules: the experience of our multidisciplinary thoracic tumor board. Cancers (Basel). 2025;17(11):1738. doi:10.3390/cancers17111738. PMID 40507220
- Lyle MA, Dean DS. Ultrasound-guided fine-needle aspiration biopsy of thyroid nodules in patients taking novel oral anticoagulants. Thyroid. 2015;25(4):373–376. doi:10.1089/thy.2014.0307. PMID 25584817
- Matynia AP, Schmidt RL, Barraza G, et al. Impact of rapid on-site evaluation on the adequacy of endoscopic-ultrasound guided fine-needle aspiration of solid pancreatic lesions: a systematic review and meta-analysis. J Gastroenterol Hepatol. 2014;29(4):697–705. doi:10.1111/jgh.12431. PMID 24783248
- Michael CW, Kameyama K, Kitagawa W, Azar N. Rapid on-site evaluation (ROSE) for fine needle aspiration of thyroid: benefits, challenges and innovative solutions. Gland Surg. 2020;9(5):1708–1715. doi:10.21037/gs-2019-catp-23. PMID 33224848
- Minaga K, Takenaka M, Katanuma A, et al. Needle tract seeding: an overlooked rare complication of endoscopic ultrasound-guided fine-needle aspiration. Oncology. 2017;93(Suppl 1):107–112. doi:10.1159/000481235. PMID 29258068
- Moss WJ, Finegersh A, Pang J, et al. Needle biopsy of routine thyroid nodules should be performed using a capillary action technique with 24- to 27-gauge needles: a systematic review and meta-analysis. Thyroid. 2018;28(7):857–863. doi:10.1089/thy.2017.0643. PMID 29742978
- Nacchio M, Di Giovanni D, Iaccarino A, et al. Analytical reliability of cell-free DNA from fine-needle aspiration rinses for BRAF and NRAS testing in metastatic melanoma. J Am Soc Cytopathol. 2026;15(3):189–196. doi:10.1016/j.jasc.2026.02.001. PMID 41951489
- Oki M, Saka H, Kitagawa C, et al. Rapid on-site cytologic evaluation during endobronchial ultrasound-guided transbronchial needle aspiration for diagnosing lung cancer: a randomized study. Respiration. 2013;85(6):486–492. doi:10.1159/000346987. PMID 23571718
- Ost DE, Folch EE, Reisenauer JS, et al. The PRECIsE study: a prospective, multicenter study of shape-sensing robotic-assisted bronchoscopy with 2 years of follow-up. Ann Am Thorac Soc. 2026;23(9):1360–1368. doi:10.1093/annalsats/aaoag049. PMID 41773028
- Pandit AA, Phulpagar MD. Worrisome histologic alterations following fine needle aspiration of the thyroid. Acta Cytol. 2001;45(2):173–179. doi:10.1159/000327273. PMID 11284302
- Park JY, Choi W, Hong AR, et al. A comprehensive assessment of the harms of fine-needle aspiration biopsy for thyroid nodules: a systematic review. Endocrinol Metab (Seoul). 2023;38(1):104–116. doi:10.3803/EnM.2023.1669. PMID 36891657
- Perez D, Stemmer MN, Khurana KK. Utilization of dynamic telecytopathology for rapid onsite evaluation of touch imprint cytology of needle core biopsy: diagnostic accuracy and pitfalls. Telemed J E Health. 2021;27(5):525–531. doi:10.1089/tmj.2020.0117. PMID 32833582
- Pitman MB, Abele J, Ali SZ, et al. Techniques for thyroid FNA: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 2008;36(6):407–424. doi:10.1002/dc.20829. PMID 18478608
- Polkowski M, Jenssen C, Kaye P, et al. Technical aspects of endoscopic ultrasound (EUS)-guided sampling in gastroenterology: European Society of Gastrointestinal Endoscopy (ESGE) Technical Guideline – March 2017. Endoscopy. 2017;49(10):989–1006. doi:10.1055/s-0043-119219. PMID 28898917
- Puttamreddy SM, Worley L, Borak S, et al. Infarction of parotid gland Warthin tumor following fine needle aspiration: a diagnostic mimicker of malignancy. Radiol Case Rep. 2026;21(10):4514–4518. doi:10.1016/j.radcr.2026.06.089. PMID 42518700
- Rekhtman N, Kazi S, Yao J, et al. Depletion of core needle biopsy cellularity and DNA content as a result of vigorous touch preparations. Arch Pathol Lab Med. 2015;139(7):907–912. doi:10.5858/arpa.2014-0392-OA. PMID 25521802
- Rivera MP, Mehta AC, Wahidi MM. Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e142S–e165S. doi:10.1378/chest.12-2353. PMID 23649436
- Roy-Chowdhuri S, Dacic S, Ghofrani M, et al. Collection and handling of thoracic small biopsy and cytology specimens for ancillary studies: guideline from the College of American Pathologists in collaboration with the American College of Chest Physicians, Association for Molecular Pathology, American Society of Cytopathology, American Thoracic Society, Pulmonary Pathology Society, Papanicolaou Society of Cytopathology, Society of Interventional Radiology, and Society of Thoracic Radiology. Arch Pathol Lab Med. 2020;144(8):933–958. doi:10.5858/arpa.2020-0119-CP. PMID 32401054
- Rusch VW, Asamura H, Watanabe H, et al. The IASLC lung cancer staging project: a proposal for a new international lymph node map in the forthcoming seventh edition of the TNM classification for lung cancer. J Thorac Oncol. 2009;4(5):568–577. doi:10.1097/JTO.0b013e3181a0d82e. PMID 19357537
- Salhab M, Al Sarakbi W, Perry N, Mokbel K. Pneumothorax after a clinical breast fine-needle aspiration of a lump in a patient with Poland's syndrome. Int Semin Surg Oncol. 2005;2:14. doi:10.1186/1477-7800-2-14. PMID 16111483
- Sarode VR, Pena V, Yan S, Kirkpatrick J, Wanzer D. Selective deployment of dynamic telecytology for rapid evaluation of cytology smears: assessment of workflow processes and role of cytopathology fellows as on-site operators. J Am Soc Cytopathol. 2021;10(6):577–584. doi:10.1016/j.jasc.2021.06.003. PMID 34238730
- Satturwar S, Rekhtman N, Lin O, Pantanowitz L. An update on touch preparations of small biopsies. J Am Soc Cytopathol. 2020;9(5):322–331. doi:10.1016/j.jasc.2020.04.004. PMID 32417160
- Sauter JL, Chen Y, Alex D, et al. Results from the 2019 American Society of Cytopathology survey on rapid onsite evaluation (ROSE)—part 2: subjective views among the cytopathology community. J Am Soc Cytopathol. 2020;9(6):570–578. doi:10.1016/j.jasc.2020.06.010. PMID 32861593
- Schmidt RL, Witt BL, Matynia AP, et al. Rapid on-site evaluation increases endoscopic ultrasound-guided fine-needle aspiration adequacy for pancreatic lesions. Dig Dis Sci. 2013;58(3):872–882. doi:10.1007/s10620-012-2411-1. PMID 23053888
- Smith EH. Complications of percutaneous abdominal fine-needle biopsy. Review. Radiology. 1991;178(1):253–258. doi:10.1148/radiology.178.1.1984314. PMID 1984314
- Steinfort DP, Khor YH, Manser RL, Irving LB. Radial probe endobronchial ultrasound for the diagnosis of peripheral lung cancer: systematic review and meta-analysis. Eur Respir J. 2011;37(4):902–910. doi:10.1183/09031936.00075310. PMID 20693253
- Tarigan TJE, Anwar BS, Sinto R, Wisnu W. Diagnostic accuracy of palpation versus ultrasound-guided fine needle aspiration biopsy for diagnosis of malignancy in thyroid nodules: a systematic review and meta-analysis. BMC Endocr Disord. 2022;22(1):181. doi:10.1186/s12902-022-01085-5. PMID 35843955
- Udoh AI, Strange T, Clement CG. Comparative accuracy of telecytology and in-person rapid on-site evaluation by specimen source: a multi-campus analysis. Ann Diagn Pathol. 2026;82:152605. doi:10.1016/j.anndiagpath.2026.152605. PMID 41604746
- VanderLaan PA, Chen Y, Alex D, et al. Results from the 2019 American Society of Cytopathology survey on rapid on-site evaluation—Part 1: objective practice patterns. J Am Soc Cytopathol. 2019;8(6):333–341. doi:10.1016/j.jasc.2019.07.007. PMID 31495750
- Vilmann P, Frost Clementsen P, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Eur J Cardiothorac Surg. 2015;48(1):1–15. doi:10.1093/ejcts/ezv194. PMID 26034060
- von Bartheld MB, van Breda A, Annema JT. Complication rate of endosonography (endobronchial and endoscopic ultrasound): a systematic review. Respiration. 2014;87(4):343–351. doi:10.1159/000357066. PMID 24434575
- Wahidi MM, Herth F, Yasufuku K, et al. Technical aspects of endobronchial ultrasound-guided transbronchial needle aspiration: CHEST guideline and expert panel report. Chest. 2016;149(3):816–835. doi:10.1378/chest.15-1216. PMID 26402427
- Wani S, Mullady D, Early DS, et al. The clinical impact of immediate on-site cytopathology evaluation during endoscopic ultrasound-guided fine needle aspiration of pancreatic masses: a prospective multicenter randomized controlled trial. Am J Gastroenterol. 2015;110(10):1429–1439. doi:10.1038/ajg.2015.262. PMID 26346868
- Wu M. A comparative study of 200 head and neck FNAs performed by a cytopathologist with versus without ultrasound guidance: evidence for improved diagnostic value with ultrasound guidance. Diagn Cytopathol. 2011;39(10):743–751. doi:10.1002/dc.21460. PMID 20949470
- Yarmus L, Akulian J, Wahidi M, et al. A prospective randomized comparative study of three guided bronchoscopic approaches for investigating pulmonary nodules: the PRECISION-1 study. Chest. 2020;157(3):694–701. doi:10.1016/j.chest.2019.10.016. PMID 31678307
- Zajdela A, Zillhardt P, Voillemot N. Cytological diagnosis by fine needle sampling without aspiration. Cancer. 1987;59(6):1201–1205. doi:10.1002/1097-0142(19870315)59:6<1201::aid-cncr2820590628>3.0.co;2-p. PMID 3815294
- Zhang C, Xie F, Li R, Cui N, Herth FJF, Sun J. Robotic-assisted bronchoscopy for the diagnosis of peripheral pulmonary lesions: a systematic review and meta-analysis. Thorac Cancer. 2024;15(7):505–512. doi:10.1111/1759-7714.15229. PMID 38286133